title: The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma.
abstract: OBJECTIVE
  Ovarian cancer has a very poor prognosis, with 5-year survival rates of 5-20% for advanced-stage disease. This work was designed to verify whether the neoadjuvant approach had an effect on survival in patients with advanced-stage ovarian cancer.
  
  
  METHODS
  Patients with stage III or IV disease who received neoadjuvant platinum-based chemotherapy (group 1) were compared with a group of conventionally treated patients (group 2).
  
  
  RESULTS
  Most of the patients in group 1 (76%) had partial tumoral responses after chemotherapy. Patients from group 1 (n = 42) had a median survival that was not different from that in patients from group 2 (n = 348). Patients who received platinum-based chemotherapy with taxanes had the same survival of patients who received no taxanes.
  
  
  CONCLUSIONS
  Our results showed similar responses and survival rates for patients with stage III or IV ovarian cancer treated with neoadjuvant platinum-based chemotherapy, when compared with patients who underwent primary suboptimal cytoreductive surgery. Our data therefore support the ongoing trials to determine the optimum timing of surgery for ovarian cancer.
authors.affiliation: Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. dornellesrosa@hotmail.com
authors.forename: D D
authors.initials: DD
authors.lastname: Rosa
authors.forename: N C
authors.initials: NC
authors.lastname: Ton
authors.forename: A
authors.initials: A
authors.lastname: Clamp
authors.forename: S
authors.initials: S
authors.lastname: Mullamitha
authors.forename: S
authors.initials: S
authors.lastname: Lau
authors.forename: R
authors.initials: R
authors.lastname: Clayton
authors.forename: H C
authors.initials: HC
authors.lastname: Kitchener
authors.forename: J H
authors.initials: JH
authors.lastname: Shanks
authors.forename: R
authors.initials: R
authors.lastname: McVey
authors.forename: G C
authors.initials: GC
authors.lastname: Jayson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D043823:Taxoids